Tag Archives: ATEC

Best Financial Stocks To Watch For 2018

DOL Fiduciary Rule Winners and Losers

DOL Fiduciary Rule Foes Say Delay Falls Short of Trump Order

Despite DOL Fiduciary Suspension, Merrill, Morgan Stanley Roll Out Products

The Securities and Exchange Commission said Wednesday that the agency has adopted amendments to increase the amount of money companies can raise through crowdfunding to adjust for inflation. 

The securities regulator also approved amendments that adjust for inflation a threshold used to determine eligibility for benefits offered to “emerging growth companies” (EGCs) under the Jumpstart Our Business Startups (JOBS) Act.

The committee voted to send Jay Clayton’s nomination to the full Senate.

You are signed up!

ThinkAdvisor and the College for Financial Planning have partnered to bring you a series of helpful educational tools that you can use to take your career to the next level. ThinkAdvisor TechCenter

ThinkAdvisor’s TechCenter is an educational resource designed to give you a competitive edge by keeping you abreast of new tech innovations and need-to-know information that can be applied to your business. Resources White Paper: Creating a Successful Transition

It’s not when you retire. It’s how you retire.

Best Financial Stocks To Watch For 2018: ARIAD Pharmaceuticals Inc.(ARIA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Healthcare shares gained around 0.73 percent in trading on Monday. Meanwhile, top gainers in the sector included Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and VCA Inc (NASDAQ: WOOF).

Best Financial Stocks To Watch For 2018: Sandstorm Gold Ltd(SAND )

Advisors’ Opinion:

  • [By Rich Duprey]

    Sandstorm Gold (NYSEMKT:SAND) has outperformed the precious metal itself over the past year, with shares rising 35% year to date. Last month it reported third-quarter profits of $7 million, a big U-turn from 2015, when it suffered losses of $5.5 million. In fact, its entire operation was doing better with greater production: lower cash costs, but higher cash margins; and greater operating cash flows, all of which allowed it to pay down its revolving credit facility. That means it has no bank debt and its entire $110 million revolving credit facility is available to make acquisitions.

Best Financial Stocks To Watch For 2018: Alphatec Holdings, Inc.(ATEC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Alphatec Holdings Inc (NASDAQ: ATEC) were down around 25 percent to $2.00 as the company reported an $18.9 million private placement.

    Heat Biologics Inc (NASDAQ: HTBX) was down, falling around 15 percent to $0.872. Heat Biologics priced its 5 million share offering at $0.80 per share.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston

stock market performance

If I have to vote for one of the strangest market reactions to a quarterly report, GoPro’s (GPRO) recent Q3’17 numbers are probably on the top of my list.

First of all, GPRO’s management had guided higher two months earlier, stating revenue will be in the upper range between $290M and $310M. Not only did it beat that number (which was already something the market did not expect), but it beat it by a whopping $20M and the revenue increase was 37% Y/Y.

If that was not enough, the company reported GAAP EPS of $0.10 and adjusted EPS of $0.15, blowing the consensus by $0.13.

And the end result was that the stock was down by about 11% on the reporting date. Supposedly, the reason for the drop was guidance that called for about $470M in revenue for Q4 vs. the $520M the market was expecting.

So is the market right or wrong? The market is dead wrong, of course, it just doesn’t know it yet. To give you just one reason why the market is wrong, please take a look at the chart below:

stock market performance: Mallinckrodt plc(MNK)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today after Citron Research accused the company of fraud.

    Getty Images

    Mallinckrodt tumbled 12% to $59.60 today, while the S&P 500 declined 0.2% to 2,176.94.

    Leerink’s Jason Gerberry and Etzer Darout explain the allegations:

    Mallinckrodtshares are down -7-8% based on a short report citing CMS dashboard data which call into question Acthar Gel sales derived from government sources (CMS; Medicaid & Medicare). The report appears to overstate Acthar CMS sales as a percent of total product sales, as the methodology utilized by CMS drug spending dashboard for Medicare spend is based on gross sales, not net., although it’s unclear to what extent Acthar CMS sales are overstated.

    The report suggestsMallinckrodt mgmt understated combined Medicaid/Medicare sales on an investor call, saying it was about a little bit higher than a quarter of the business vs. gross sales on CMS dashboard implying sales were 61% of total Acthar net revenue (an apples to oranges comparison). We dont know the exact net sales of Acthar to Medicare/Medicaid, but we believe it is safe to assume Medicaid, after CPI price penalties had high discounts/rebates and assuming an 80% gross-to-net ratio on the Medicare book ($504m gross) suggests Acthar net sales would be closer to 38-45% range vs. the 61% figure cited in the short-report. Why this may matter Acthar Gel is an old product lacking good randomized, controlled data consistent with most products approved in the modern era. The report appears to be an attempt to call into question whether the government should be paying Acthars average $80-100k net price/patient/year by calling to this to the attention of government figures who have been targeting excessive drug pricing issues. This type of issue became a major headache for Mylan (MYL) investors recently with EpiPen.Mallinckrodt is presenting at a compe

  • [By Keith Speights]

    That’s the question investors are trying to answer about how President Trump’s policies might impact healthcare stocks. So far, specific policy proposals put forward by the president appear likely to cause significant problems for certain healthcare stocks. Here’s why three of President Trump’s policies could be downright terrible for Molina Healthcare(NYSE:MOH), Mallinckrodt (NYSE:MNK), and Illumina (NASDAQ:ILMN).

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today after its earnings topped the Street consensus but offered commentary that spooked investors.

    Agence France-Presse/Getty Images

    Shares of Mallinckrodt dropped 9.1% to $52.42, while the S&P 500 rose 0.1%.

    Barclays analyst Douglas Tsao and Morgan Williams callMallinckrodt’s plunge “outsized.” They explain why:

    In our view the sell-off afterMallinckrodt reported CY3Q16 earnings is outsized considering much of the disclosure on the call was largely expected, including specialty generics weakness and the 2017 outlook, which seemed relatively mild. While outsized Acthar contribution to EBITDA may be accounting for some of the sell-off, wed argue that there is benefit to the brand outperforming, especially considering the need to offset Therakos production issues in CY4Q16 and CY1Q17 as well as specialty generics weakness. We recognize some lingering headline risk associated with media reports criticizing the cost of Acthar to Medicare, after CMS released its prescription drug spending dashboard.

    Mallinckrodt’s market capitalization fell to $5.7 billion today from $6.2 billion yesterday. It reported net income of $306 million on revenue of $3.3 billion in 2015.

    This marks the third time in less than two weeks that Mallinckrodt was the S&P 500′s biggest loser.

  • [By Johanna Bennett]

    Sell-side analysts continue to defend drug maker Mallinckrodts (MNK) shares on the heel of Citron Researchs report on the company released last week.

    Earlier today, UBS analyst Marc Goodman and his team weighed into the fray, proclaiming that a misunderstood situation creates opportunity.

    Goodman, who rates Mallinckrodt at a buy with a $92 price target, argues that Mallinckrodt is a different breed from other specialty drug makers, with high-quality earnings, sales growth fueled by volume not price hikes and an emerging pipeline we think is not just underappreciated but really not even part of the conversation with most investors.

    Also, he argues that Mallinckrodt continues to be misunderstood by investors.

    Goodman goes into goes into more detail:

    we were surprised this past week by the debate around Acthar’s Medicare exposure (~30% or ~40%), which in our view has little relevance to the overall MNK story. The key debate since the Questcor deal has been Acthar payer coverage and concerns for more barriers andor coverage blocks by the payers. There was reason for concern just 2 years ago, in our view, as several important payers increased barriers. But mgt’s aggressive focus on enhancing clinical and health-economics data to help support better coverage seems to be working and has resulted in improved coverage, which we believe is still not well appreciated.

    Mallinckrodt shares continue to climb today, rising 4.8% to a recent $57.20.

stock market performance: WashingtonFirst Bankshares Inc(WFBI)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of CASTLE CREEK CAPITAL PARTNERS IV, LP’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=CASTLE+CREEK+CAPITAL+PARTNERS+IV%2C+LP

    These are the top 5 holdings of CASTLE CREEK CAPITAL PARTNERS IV, LPGuaranty Bancorp (GBNK) – 1,448,849 shares, 39.1% of the total portfolio. MBT Financial Corp (MBTF) – 1,876,423 shares, 23.6% of the total portfolio. WashingtonFirst Bankshares Inc (WFBI) – 489,377 shares, 15.19% of the total portfolio. Shares added by 4558.07%Eastern Virginia Bankshares Inc (EVBS) – 1,061,225 shares, 12.33% of the total portfolio. First NBC Bank Holding Co (FNBC) – 2,205,382 shares, 9.78% of the total portfolio. Added: Wa

stock market performance: Monotype Imaging Holdings Inc.(TYPE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Monotype Imaging Holdings Inc. (NASDAQ: TYPE) were down around 12 percent to $20.90 after the company posted downbeat quarterly earnings.

  • [By Lisa Levin]

    Wednesday afternoon, the non-cyclical consumer goods & services shares surged 0.61 percent. Meanwhile, top gainers in the sector included Monotype Imaging Holdings Inc. (NASDAQ: TYPE), up 9 percent, and Semiconductor Manufacturing Int'l (ADR) (NYSE: SMI), up 6 percent.

stock market performance: CGG(CGG)

Advisors’ Opinion:

  • [By Jonas Elmerraji]

    First up is French oil service firm CGG Veritas (CGG)
    . The Eurozone-based energy stock hasn’t exactly posted blockbuster performance in 2013, but investors who ignore CGG for the final stretch of the year could be making a big mistake. That’s because of a bullish technical pattern that’s emerging in shares right now.

    CGG spent most of the last eight months looking anything but bullish. But an ascending triangle pattern is changing that. The pattern is formed by horizontal resistance to the upside at $26, and uptrending support to the below shares. Basically, as CGG bounces in between those two technical levels, it’s getting squeezed closer and closer to a breakout above $26. When that happens, traders have a buy signal.

    The ascending triangle pattern in CGG Veritas isn’t exactly textbook. That’s because the setup is forming at the bottom of a downtrend, rather than in the middle of an uptrend – but it’s a mistake to get caught up on the textbook pictures of what trading patterns are supposed to look like. On a move through $26, the trading implications are just as actionable.

  • [By Lisa Levin]

    CGG SA (ADR) (NYSE: CGG) shares shot up 32 percent to $7.15 after the company reported an agreement in principle on financial restructuring plan with main creditors and DNCA.

  • [By Lisa Levin]

    Friday afternoon, the energy sector proved to be a source of strength for the market. Leading the sector was strength from CGG SA (ADR) (NYSE: CGG) and Geospace Technologies Corporation (NASDAQ: GEOS).

stock market performance: Alphatec Holdings, Inc.(ATEC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Alphatec Holdings Inc (NASDAQ: ATEC) were down around 25 percent to $2.00 as the company reported an $18.9 million private placement.

    Heat Biologics Inc (NASDAQ: HTBX) was down, falling around 15 percent to $0.872. Heat Biologics priced its 5 million share offering at $0.80 per share.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston

Top 10 Safest Stocks To Buy For 2018

The Centers for Medicare & Medicaid Services has announced Medicare Part B premiums for 2018, and the base premium stays the same as this year at $134 a month, but a lot actually changes. For 70% of Social Security recipients who have been paying an artificially low $109 a month, theyll see a big jump to the $134 a month level. Also, many high earnersstarting at $133,500 for a single–will face higher high-income surcharges.  Part B (the base and the surcharge) covers doctors and outpatient services.

The backdrop to the premium jump for the 70% of folks is that the Social Security Administration announced a 2% cost of living adjustment (COLA) for 2018 last month. The average benefit for a retired worker will rise by $27 a month to $1,404 in 2018. Many recipients will find most or all of their increase eaten up by the jump in the Medicare Part B premiums deducted from their monthly Social Security checks. A hold harmless provision (no increase in Medicare premiums can reduce a Social Security recipients net monthly check) kept their premiums in check before.

Top 10 Safest Stocks To Buy For 2018: General Motors Company(GM)

Advisors’ Opinion:

  • [By Paul Ausick]

    General Motors Co. (NYSE: GM) on Friday posted total November U.S. sales of 245,387 vehicles, a decrease of 2.9% compared with November 2016. Retail deliveries dropped 0.1% in the month to 197,340 units, and fleet deliveries rose to 19.6% for the month. Fleet sales now account for 19.4% of 2017 sales.

  • [By Douglas A. McIntyre]

    General Motors Co. (NYSE: GM) launched its own version of the electric car recently. The Chevy Bolt is available across the country at a price of $37,495. After federal tax credits, that figure falls to $29,995.

  • [By Kumar Abhishek]

    Ironically, one of the biggest catalysts for Tesla stock has been Elon Musk’s nomination to President Donald Trump’s business advisory board. According to Morgan Stanley analyst Adam Jonas, “Elon Musk has an important line of communication to Donald Trump,” which is a big development for the company. Just after the election, one of the biggest fears for Tesla stockholders was that theTrump administration would roll back environmental regulations and encourage coal and oil production. However, a couple of weeks after the elections, the narrative completely changed with Tesla emerging as the poster boy of “US manufacturing”, one of the main focuses of the current administration. Unlike its rivals such as Ford (NYSE:F) and General Motors (NYSE:GM) Tesla makes almost all of its cars and solar energy products inside the US. According to Bloomberg, the company is likely to be the biggest gainer if the border tax is imposed.

Top 10 Safest Stocks To Buy For 2018: Rhino Resource Partners LP(RNO)

Advisors’ Opinion:

  • [By Alexis Xydias]

    Investors are regaining confidence, squeezing pessimists who say the economy remains sluggish outside of Germany and point to record-low trading volume as a lack of conviction in the Euro Stoxxs 61 percent rally of the past two years. Besides gains in stocks from Banco Bilbao Vizcaya Argentaria SA to Renault SA (RNO), yields on Spanish and Italian bonds have declined to a two-year low compared with German bunds and the euro has strengthened 4.6 percent to $1.35 in the past six months.

Top 10 Safest Stocks To Buy For 2018: Vanguard FTSE Europe ETF (VGK)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    Perhaps the largest ETF dedicated to tracking French stocks should be getting more attention. In a year in which ETFs tracking the PIIGS economies are struggling, EWQ has been solid. The France ETF's 2.7 percent year-to-date gain is slightly ahead of the comparable Germany ETF and more than twice as good as the Vanguard FTSE Europe ETF (NYSE: VGK).

  • [By Todd Shriber, ETF Professor]

    Still, there are instances of limited appetite for diversified Europe ETFs, particularly those with significant U.K. exposure. The Vanguard FTSE Europe ETF (NYSE: VGK) hasn't added (or lost) any capital since June 20. That ETF devotes 31.4 percent of its weight to U.K. stocks.

  • [By Tom Aspray, Senior Editor, MoneyShow.com]

    The US stock market is still leading with the Spyder Trust (SPY) up 18.6%, while the European markets (VGK) are now up close to 10% for the year, as they have gotten a nice boost in the past three weeks.

  • [By Todd Shriber, ETF Professor]

    Here is a dichotomy. Global small-caps are performing admirably. The WisdomTree Europe SmallCap Dividend Fund (NYSE: DFE) is an example of a Europe ETF that is defying some unfavorable trends. DFE is down 3.5 percent year-to-date. That sounds bad, but it is far better than what investors have been treated to with diversified, large-cap Europe ETFs. The Vanguard Europe ETF (NYSE: VGK) and the iShares Europe ETF (NYSE: IEV) are down an average of 5.3 percent this year.

Top 10 Safest Stocks To Buy For 2018: Alphatec Holdings, Inc.(ATEC)

Advisors’ Opinion:

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Lisa Levin]

    Shares of Alphatec Holdings Inc (NASDAQ: ATEC) were down around 25 percent to $2.00 as the company reported an $18.9 million private placement.

    Heat Biologics Inc (NASDAQ: HTBX) was down, falling around 15 percent to $0.872. Heat Biologics priced its 5 million share offering at $0.80 per share.

Top 10 Safest Stocks To Buy For 2018: Geopark Ltd(GPRK)

Advisors’ Opinion:

  • [By Dustin Parrett]

    As a service to our readers, we’ve put together a list of 10 cheap oil stocks under $5. Here are the stocks, share prices, and year-to-date (YTD) returns for each:

    Vallourec Sp (OTCMKTS ADR: VLOWY); $1.42; +13.6% YTDIthaca Energy Inc. (TSE: IAE); $1.93; +14.5% YTDSandRidge Permian Trust (NYSE: PER); $3.45; +16.95% YTDGeopark Ltd. (NYSE: GPRK); $5.06; +17.4% YTDGastar Exploration Inc. (NYSEMKT: GST); $1.89; +22.26% YTDAscent Resources Plc. (LON: AST); $2.11; +25.53% YTDErin Energy Corp. (NYSEMKT: ERN); $3.94; +29.1% YTDChesapeake Granite Wash Trust (NYSE: CHKR); $3.25; +38.3% YTDSouthcross Energy Partners LP (NYSE: SXE); $2.27; +68.15% YTDBonanza Creek Energy Inc. (NYSE: BCEI); $2.27; +122.55% YTD

    This list of oil stocks contains some highly speculative plays, so we can’t recommend buying them.

Top 10 Safest Stocks To Buy For 2018: SCIENCE APPLICATIONS INTERNATIONAL CORPORATION(SAIC)

Advisors’ Opinion:

  • [By Monica Gerson]

    Wall Street expects Science Applications International Corp (NYSE: SAIC) to report its quarterly earnings at $0.74 per share on revenue of $1.15 billion. SAIC shares gained 0.96 percent to $57.87 in after-hours trading.

  • [By Monica Gerson]

    Science Applications International Corp (NYSE: SAIC) is estimated to report its quarterly earnings at $0.74 per share on revenue of $1.15 billion.

  • [By Lisa Levin]

    Gainers

    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

Top 10 Safest Stocks To Buy For 2018: RetailMeNot, Inc.(SALE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of RetailMeNot Inc (NASDAQ: SALE) got a boost, shooting up 12 percent to $8.42. RetailMeNot announced after Thursday’s close it has entered into an agreement to acquire GiftCard Zen, a secondary marketplace for gift cards. The company reported preliminary Q1 revenue of $54 million to $54.5 million and FY16 revenue of $228 million to $241 million.

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, RetailMeNot (NASDAQ:SALE) and SUPERVALU (NYSE:SVU) attracted heavy investor interest following merger and acquisition news.

Top 10 Safest Stocks To Buy For 2018: Heartware International, Inc.(HTWR)

Advisors’ Opinion:

  • [By Spencer Israel]

    4. HeartWare International Inc (NASDAQ: HTWR) – The heart device maker agreed to be acquired by Medtronic for $58 per share in cash two weeks ago. Prior to that the stock had been trading just above $30. 

Top 10 Safest Stocks To Buy For 2018: MGIC Investment Corporation(MTG)

Advisors’ Opinion:

  • [By Brian Feroldi, Chuck Saletta, Tyler Crowe, Jason Hall, and Jordan Wathen]

    With that in mind, we asked a team of Fools each to highlight a stock that a billionaire investor has been selling recently. Read on to see why they chose Cheniere Energy (NYSEMKT:LNG), Activision Blizzard (NASDAQ:ATVI), Suncor Energy (NYSE:SU), MGIC Investment Corporation (NYSE:MTG), and Extended Stay America (NYSE:STAY).

Top 10 Safest Stocks To Buy For 2018: Valhi Inc.(VHI)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, basic materials shares slipped by 0.61 percent. Meanwhile, top losers in the sector included Valhi, Inc. (NYSE: VHI), down 13 percent, and LSB Industries, Inc. (NYSE: LXU), down 7 percent.

Top Bank Stocks To Watch For 2018

We all know financial stocks have gone through the roof since President Trump’s win. So the question becomes: what do we do with these companies now?

There’s no one answer for every financial stock, of course.

Some are still great, undervalued buys—but there are two that have gotten grossly overvalued and should be avoided, or sold if you hold them. (Below, I’ll reveal 3 better high-yield stocks to buy instead.)

These 2 Financials Are Headed for Trouble

Bank of America Corp (BAC) is the first bank on my hit list.

A Breathtaking Rise

After spending most of 2016 in the red, BAC has soared more than 37% in three months. Nothing much has changed at the bank; it’s just riding a wave of euphoria as investors bet that Trump’s America will mean higher interest rates and fewer regulations, driving up BAC’s earnings.

Top Bank Stocks To Watch For 2018: Alphatec Holdings, Inc.(ATEC)

Advisors’ Opinion:

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Lisa Levin]

    Shares of Alphatec Holdings Inc (NASDAQ: ATEC) were down around 25 percent to $2.00 as the company reported an $18.9 million private placement.

    Heat Biologics Inc (NASDAQ: HTBX) was down, falling around 15 percent to $0.872. Heat Biologics priced its 5 million share offering at $0.80 per share.

Top Bank Stocks To Watch For 2018: Panasonic Corporation (PCRFY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Clean Technica reported on September 1 that “Sony is entering the EV battery manufacturing industry”. And “considering that electric vehicle batteries are going to be the main supply bottleneck for the upcoming auto market’s embrace of EVs, the entry of Sony into the field is very notable. Most of the other manufacturers (Panasonic (OTCPK:PCRFY), LG Chem (OTC:LGCLF), etc.) already have more or less all of their production capacity locked up for the coming years – meaning there’s not much left for the auto manufacturers that are running behind, thereby limiting potential EV sales for the firms in question. Sony’s (NYSE:SNE) entry into the field should open things up a bit more”. Certainly a good move by Sony and helpful for the EV companies that will find themselves in need of batteries, and limited availability, should EVs reach 10% by 2020.

  • [By Ben Levisohn]

    During the early stages of a new innovation, interdependent architectures and integrated companies best optimize performance and functionality. This trend has played out in computing and handsets, and we see the same trend playing out in EVs. We find Tesla and BYD1 , by far, the most vertically integrated players in EVs, with huge scale advantages. In addition, LG Chem, Panasonic (PCRFY), Samsung SDI, BYD, and CATL are clear scale leaders in batteries (CATL is not publicly traded. All but Samsung SDI and BYD are not covered by Bernstein.).

  • [By SEEKINGALPHA.COM]

    SMMYY is a subsidiary of the Sumitomo Group. SMMYY is a major smelter and refiner of copper, nickel and gold in Japan, and has a 27.5% stake in the Ambatovy Nickel Project in Madagascar, along with Sherritt International and Korea Resources Corp. Feedstock for the refinery is nickel cobalt mixed sulphide from its Taganito and Coral Bay mines in the Philippines (noting the Philippines is a risky supply source at this time). Sumitomo supply Panasonic (OTCPK:PCRFY) who supply Tesla (NASDAQ:TSLA); however, this can change. Generally, I like the stock; however, at this time, valuation looks full, trading on a 2017 PE of 32.8, and 2018 PE of 14.8. Good to buy after a pullback if that occurs.

  • [By SEEKINGALPHA.COM]

    A Unilever vs. Panasonic (OTCPK:PCRFY) showdown seems to be something out of an alternative, weird universe. But that’s exactly what has been happening in the Asia-Pacific region, where Unilever is now a major seller of air and water purification devices. The acquisitions of Qinyuan and Pureit water purifiers, as well as the acquisition of Sweden-based Blueair in 2016, reflects Unilever’s latest growth strategy of reducing exposure to low-growth brands in favor of greater investments in higher-growth products with strong social and environmental credentials.

Top Bank Stocks To Watch For 2018: Intercept Pharmaceuticals, Inc.(ICPT)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap liver biopharmaceutical stock Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reportedQ2 2017 earnings before the market opened on Monday with both the top and bottom lines beating expectations plus the Companyreported that amid-stage clinical trial met its primary endpoint; but sharesended the day down13.26%. Intercept Pharmaceuticals recognized $30.4 million of net sales of Ocaliva for Q2 2017 versus $75k and a net loss of $86.6 million versus a net loss of $77.3 million. Ocaliva was approved by the U.S.FDA in May 2016 for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. As of June 30, 2017,the Companyhad cash, cash equivalents and investment securities available for sale of approximately $550.3 million versus$689.4 million as of December 31, 2016. The CEO commented:

  • [By Paul Ausick]

    Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) dropped more than 17% Friday to post a new 52-week low of $60.97 after closing Thursday at $73.70. The 52-week high is $172.75. Volume of more than 10 million shares traded was about 12 times the daily average. The FDA on Thursday issued a warning letter on the company’s liver disease treatment.

Top Bank Stocks To Watch For 2018: Realogy Holdings Corp.(RLGY)

Advisors’ Opinion:

  • [By Lisa Abramowicz]

    Drugstore chain Rite Aid Corp. (RAD) and residential property firm Realogy Corp. (RLGY) are two of the 283 junk-rated borrowers identified in March 2009 by Moodys Investors Service as being at the highest risk of default that have since sold bonds.

  • [By Monica Wolfe]

    Realogy Holdings (RLGY)

    Paulsons third largest holding goes to Realogy Holdings. The guru holds on to 12,957,700 shares, representing 4.4% of his total portfolio and 8.87% of the companys shares outstanding.

  • [By Chad Tracy]

    Investments in Claire's retail stores, Realogy Holdings (NYSE: RLGY), and Harrah's Entertainment all came under pressure as the global credit crisis hit. Apollo was forced to shut off cash interest payments to investors and to issue more debt.  

Top Bank Stocks To Watch For 2018: Neptune Technologies & Bioresources Inc(NEPT)

Advisors’ Opinion:

  • [By Monica Gerson]

    Neptune Technologies & Bioressources (NASDAQ: NEPT) is projected to post a quarterly loss at $0.01 per share on revenue of $9.70 million.

    Apigee Corp (NASDAQ: APIC) is expected to post a quarterly loss at $0.27 per share on revenue of $23.17 million.

  • [By Jim Robertson]

    Yesterday, our Under the Radar Movers newsletter suggested small cap functional ingredient stock Neptune Technologies & Bioressources (NASDAQ: NEPT) as a long/bullish trade:

Top Bank Stocks To Watch For 2018: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Trevena Inc (NASDAQ: TRVN) shares dropped 36 percent to $4.55 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called "APOLLO-1" and "APOLLO-2." The studies evaluated the safety of Trevena's oliceridine therapy in patients for 48 hours following bunionectomy and 24 hours following abdominoplasty.

  • [By Chris Lange]

    Trevena Inc. (NASDAQ: TRVN) reported positive results from two late-stage clinical trials that work to treat post-surgical pain. The company intends to submit these results to the FDA for a marketing approval agreement in the fourth quarter. Previously, oliceridine was approved for a breakthrough designation by the agency.

  • [By Maxx Chatsko]

    Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn’t announce any surprises one way or the other. However, investors appear to be considering the near-term consequences of swelling expenses that won’t be offset by product sales anytime soon.

  • [By Paul Ausick]

    Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.

Best High Tech Stocks To Buy Right Now

On January 26, microprocessor giant Intel (NASDAQ:INTC) will report its financial results and provide financial guidance for the coming quarter and, likely, the entirety of 2017.

Although the company is planning to host its financial analyst day shortly thereafter, on February 9, during which the company will go into deeper dives into each of its business units, there are still several questions I’d like to hear answered during the company’s upcoming earnings call. Here are three.

Will the memory business be profitable this year?

Over the course of 2016, Intel’s non-volatile memory business — which builds and sells products based mainly on NAND flash and will soon begin shipping products based on its 3D XPoint technology — has lost a bunch of money.

A NAND flash-based solid-state drive. Image source: Intel.

The losses Intel has racked up here during the first three quarters of 2016 are $453 million, with more losses likely on the way during the fourth quarter.

Best High Tech Stocks To Buy Right Now: Alphatec Holdings, Inc.(ATEC)

Advisors’ Opinion:

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Lisa Levin]

    Shares of Alphatec Holdings Inc (NASDAQ: ATEC) were down around 25 percent to $2.00 as the company reported an $18.9 million private placement.

    Heat Biologics Inc (NASDAQ: HTBX) was down, falling around 15 percent to $0.872. Heat Biologics priced its 5 million share offering at $0.80 per share.

Best High Tech Stocks To Buy Right Now: BioAmber Inc.(BIOA)

Advisors’ Opinion:

  • [By Paul Ausick]

    BioAmber Inc. (NYSE: BIOA) dropped nearly 29% Friday to post a new 52-week low of $2.24 after closing Thursday at $3.14. Volume of more than 1.5 million shares was about 6 times the daily average of around 240,000. The company’s annual report, filed on Thursday with its quarterly results, included a “going concern” statement from the company’s independent auditing firm.

  • [By Markus Aarnio]

    BioAmber (BIOA) is a sustainable chemicals company. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in a wide variety of everyday products including plastics, resins, food additives and personal care products.

  • [By Lisa Levin]

    Bioamber Inc (NYSE: BIOA) shares dropped 19 percent to $2.55. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
    Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
    The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
    Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
    Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
    Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
    AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
    Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli

Best High Tech Stocks To Buy Right Now: Greenlight Capital Re Ltd.(GLRE)

Advisors’ Opinion:

  • [By Jim Robertson]

    Note that hedge fund mogul David Einhorn has been a director ofthe predecessor company since May 2006. Mr. Einhorn co-founded, and has served as the President of, Greenlight Capital, Inc., since January 1996. Funds managed by Greenlight are some ofthe Companys principal stockholders. Since July 2004, Mr. Einhorn has served as Chairman of the Board of Greenlight Capital Re, Ltd (Nasdaq: GLRE).

Best High Tech Stocks To Buy Right Now: Ormat Technologies, Inc.(ORA)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of U.S. Geothermal back in positive territory while potential peer mid cap Calpine Corporation (NYSE: CPN) is underperforming and Ormat Technologies, Inc (NYSE: ORA) has been taking off for two years:

Best High Tech Stocks To Buy Right Now: Piedmont Natural Gas Company Inc.(PNY)

Advisors’ Opinion:

  • [By WWW.KIPLINGER.COM]

    Duke also recently has expanded on its natural gas efforts, and will add numerous more natural gas customers when its buy-out of Piedmont Natural Gas Company, Inc. (PNY) goes through.